Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
19 angezeigte Treffer · Seite 5, keine Gesamtzahl für „Venclyxto“
Suchtreffer
Begriffe & Kennungen
Venclyxto · 4.8 · Respiratory, Very common Dyspnoea thoracic, and mediastinal disorder Common Dyspnoea Nausea Diarrhoea Very com
Eintrag öffnenVenclyxto · 4.8 · Summary of safety profile
Eintrag öffnenVenclyxto · 4.8 · System organ class Frequency All gradesa Grade ≥3a Pneumonia Upper respiratory tract Very common infection Inf
Eintrag öffnenVenclyxto · 4.8 · System organ class Frequency All gradesa Grade ≥3a Pneumoniab Pneumoniab Infections and Very common Sepsisb Se
Eintrag öffnenVenclyxto · 4.8 · Tabulated list of adverse reactions Adverse reactions are listed below by MedDRA body system organ class and b
Eintrag öffnenVenclyxto · 4.8 · The 30-day mortality rate in the M14-358 study with venetoclax in combination with decitabine was 6.5% (2/31).
Eintrag öffnenVenclyxto · 4.8 · The 30-day mortality rate in the VIALE-A study was 7.4% (21/283) with venetoclax in combination with azacitidi
Eintrag öffnenVenclyxto · 4.8 · The frequencies of adverse reactions reported with Venclyxto in combination with a hypomethylating agent in pa
Eintrag öffnenVenclyxto · 4.8 · The frequencies of adverse reactions reported with Venclyxto, in combination with obinutuzumab, ibrutinib, or
Eintrag öffnenVenclyxto · 4.8 · The most commonly occurring adverse reactions (≥20%) of any grade in patients receiving venetoclax in the comb
Eintrag öffnenVenclyxto · 4.8 · The most frequently reported serious adverse reactions (≥5%) in patients receiving venetoclax in combination w
Eintrag öffnenVenclyxto · 4.8 · The overall safety profile of Venclyxto is based on data from 1187 patients with CLL treated in clinical studi
Eintrag öffnenVenclyxto · 4.8 · The overall safety profile of Venclyxto is based on data from 314 patients with newly diagnosed acute myeloid
Eintrag öffnenVenclyxto · 4.8 · The risk of TLS was reduced after revision of the dosing regimen and modification to prophylaxis and monitorin
Eintrag öffnenVenclyxto · 4.8 · The safety of venetoclax in combination with acalabrutinib with or without obinutuzumab was assessed in AMPLIF
Eintrag öffnenVenclyxto · 4.8 · Tumour lysis syndrome
Eintrag öffnenVenclyxto · 4.8 · Tumour lysis syndrome is an important identified risk when initiating venetoclax.
Eintrag öffnenVenclyxto · 4.8 · Uncommon Constipation
Eintrag öffnenVenclyxto · 4.8 · Uncommon Tumour lysis syndrome Dizziness/syncopeb Very common Headache Nervous System Common Dizziness/syncope
Eintrag öffnen